IQVIA announces offering of €950 million senior notes
Proceeds will refinance existing indebtedness and pay fees. The notes are due 2033 and offered privately.
See the latest news and media coverage for IQVIA. We track all announcements, press releases, and industry mentions in real time, all in one place.
Life sciences data, analytics, and clinical research company
iqvia.comLast updated
In short: IQVIA delivered record Q1 2026 earnings, raised its full-year outlook, and launched a unified AI platform, IQVIA.ai, in partnership with NVIDIA.
Proceeds will refinance existing indebtedness and pay fees. The notes are due 2033 and offered privately.
This raises the total authorization to $3.2 billion under the existing program. Repurchases depend on market conditions and have no expiration date.
Revenue reaches $4,151 million, up 8.4%. Adjusted EBITDA is $932 million. Raises full-year EPS guidance to $12.65-$12.95.
The study in Belgium compares Control IQ technology with conventional insulin therapy for type 1 diabetes adults using IQVIA CORE Diabetes Model. It provides insights for access and reimbursement.
Morgan Stanley upgraded contract research organization (CRO) provider Charles River Laboratories while downgrading IQVIA, arguing that improving biotech funding and portfolio changes create a more...
In other recent news, IQVIA Holdings Inc. has announced the pricing of €950 million in senior notes due in 2033. These notes will carry an...
Over the last six months, IQVIA’s shares have sunk to $177.52, producing a disappointing 19.8% loss - a stark contrast to the S&P 500’s 12.4...
IQVIA Holdings Inc. IQV is benefiting from strong demand for its vast data resources, favorable...
Track IQVIA and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.